Comparison of sunlight-AOPs for levofloxacin removal: kinetics, transformation products, and toxicity assay on Escherichia coli and Micrococcus flavus.

Levofloxacin (LFX) is a widely used antibiotic medication. Persistent traces of LFX in water and wastewater may induce bacterial resistance. Photon-driven advanced oxidation processes (AOPs) can assist in attaining complete abatement of LFX for environmental protection. This work benchmarks different solar AOPs based on hydroxyl radical (OH•) and sulphate radical (SO4•-) chemistry. Other oxidant precursors, as radical sources, were used to selectively control the generation of either hydroxyl radical (i.e., H2O2), sulphate radical (i.e., peroxydisulphate (PDS)), or a controlled mixture ratio of both OH•/SO4•- (i.e., peroxymonosulphate (PMS)). The influence of pH on degradation performance was evaluated using unbuffered and buffered solutions. Simulated irradiation/PMS process exhibited a strong pH-dependence attaining partial degradation of ca. 56% at pH 5 up to complete degradation at pH 7. Despite the similitudes on the abatement of target pollutant LFX in pristine solutions, only simulated irradiation/PDS treatment achieved effective abatement of LFX in wastewater samples given the higher selectivity of SO4•-. Toxicity tests were conducted with Escherichia coli (LMG2092) and Micrococcus flavus (DSM1790), demonstrating successful inhibition of the antibiotic character of polluted waters, which would contribute to preventing the development of resistant bacterial strains. Finally, a degradative pathway was suggested from the by-products and intermediates identified by LC-MS. Results demonstrate that the degradation of specific functional groups (i.e., piperazine ring) is associated with the loss of antibacterial character of the molecule.

Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Since coronavirus disease 2019 (COVID-19) started as a fast-spreading pandemic, causing a huge number of deaths worldwide, several therapeutic options have been tested to counteract or reduce the clinical symptoms of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, no specific drugs for COVID-19 are available, but many antiviral agents have been authorised by several national agencies. Most of them are under investigation in both preclinical and clinical trials; however, pharmacokinetic and metabolism studies are needed to identify the most suitable dose to achieve the desired effect on SARS-CoV-2. Therefore, the efforts of the scientific community have focused on the screening of therapies able to counteract the most severe effects of the infection, as well as on the search of sensitive and selective analytical methods for drug detection in biological matrices, both fluids and tissues. In the last decade, many analytical methods have been proposed for the detection and quantification of antiviral compounds currently being tested for COVID-19 treatment. In this review, a critical discussion on the overall analytical procedure is provided, i.e (a) sample pre-treatment and extraction methods such as protein precipitation (PP), solid-phase extraction (SPE), liquid-liquid extraction (LLE), ultrasound-assisted extraction (UAE) and QuEChERS (quick, easy, cheap, effective, rugged and safe), (b) detection and quantification methods such as potentiometry, spectrofluorimetry and mass spectrometry (MS) as well as (c) methods including a preliminary separation step, such as high performance liquid chromatography (HPLC) and capillary electrophoresis (CE) coupled to UV-Vis or MS detection. Further current trends, advantages and disadvantages and prospects of these methods have been discussed, to help the analytical advances in reducing the harm caused by the SARS-CoV-2 virus.